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Abstract
Background: There is currently little patient information on bronchiectasis, a chronic lung disease with rising
prevalence. Previous work shows that patients and their families want more information, which could potentially
improve their understanding and self-management. Using interviews and focus groups, we have co-developed a
novel patient and carer information resource, aiming to meet their identified needs.
The aims and objectives are:
1. To assess the potential impact of the information resource
2. To evaluate and refine the intervention
3. To establish the feasibility of carrying out a multi-centre randomised controlled trial to determine its effect on
understanding, self-management and health outcomes
Methods/design: This is a feasibility study, with a single-centre, randomised controlled trial design, comparing use
of a novel patient information resource to usual care in bronchiectasis. Additionally, patients and carers will be
invited to focus groups to discuss their views on both the intervention itself and the trial process.
The study duration for each participant will be 3 months from the study entry date. A total of 70 patients will be
recruited to the study, and a minimum of 30 will be randomised to each arm. Ten participants (and their carers if
applicable) will be invited to attend focus groups on completion of the study visits. Participants will be adults with
bronchiectasis diagnosed as per national bronchiectasis guidelines.
Once consented, participants will be randomised to the intervention or control arm using random permuted blocks
to ensure treatment group numbers are evenly balanced. Randomisation will be web-based. Those randomised to
the intervention will receive the information resource (website and booklet) and instructions on its use. Outcome
measures (resource satisfaction, resource use and alternative information seeking, quality of life questionnaires,
unscheduled healthcare visits, exacerbation frequency, bronchiectasis knowledge questionnaire and lung function
tests) will be recorded at baseline, 2 weeks and 3 months.
Discussion: All outcome measures will be used in assessing feasibility and acceptability of a future definitive trial.
Feasibility outcomes include recruitment, retention and study scale form completion rates. Focus groups will
strengthen qualitative data for resource refinement and to identify participant views on the trial process, which will
also inform feasibility assessments. Questionnaires will also be used to evaluate and refine the resource.
Trial registration: ISRCTN84229105
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Background
Bronchiectasis is a chronic lung condition, characterised
by dilated bronchi, leading to symptoms of breathlessness
and chronic productive cough, with intermittent infective
exacerbations. Bronchiectasis has various potential aetiol-
ogies including immune deficiency syndromes, chronic
asthma, chronic obstructive pulmonary disease, ciliary
dysfunction and post-infectious causes, yet studies have
found that between a quarter and half of cases are idio-
pathic [1, 2]. Patients often have recurrent, costly hos-
pital admissions, a poorer quality of life [3, 4] and
clinically significant fatigue [5, 6].
Current estimates suggest a rise in prevalence in the
UK and indicate a prevalence of between 43.4/100,000
in those aged 18–30 and 1239.7/100,000 in those aged
70–79 [7]. Importantly, studies demonstrate that up to
50 % of patients with chronic obstructive pulmonary dis-
ease (COPD) have co-existent bronchiectasis [8]. There
are approximately 1,000,000 patients with COPD in the
UK [9]; thus there is potential for a significant increase
in case finding of COPD-associated bronchiectasis over
the coming years.
Bronchiectasis mortality rates are approximately 50 %
higher than that of uncomplicated COPD (calculated at
3 % per annum) and are increasing [10]. The prognosis
varies, with a recent study of 91 patients [11] finding
that the primary cause of death was usually respiratory,
with survival rates of 91 % at 4 years and 68.3 % at
12.3 years. Infective exacerbations lead to significant mor-
bidity. Previously published UK data also emphasise the
burden of bronchiectasis, uncertainties in aetiology and
lack of evidence for the treatments that are often used
[12]. This is consistent with recently published American
data on the increasing burden of bronchiectasis [13].
There is no cure for bronchiectasis. Current modalities
of treatment include oral, inhaled or intravenously ad-
ministered antibiotics, used both regularly and with
additional courses for exacerbations. Mucolytics and
regular physiotherapy are used to aid sputum clearance,
and additional guidelines for investigation, diagnosis
and management of bronchiectasis have been provided by
the British Thoracic Society (BTS) [14]. Inappropriate
antibiotic use can lead to antibiotic resistance. Conversely,
not commencing antibiotics promptly can result in a
severe exacerbation requiring costly hospital admission.
Bronchiectasis differs from many chronic diseases in that
appropriate, timely recognition of symptoms and improved
management of infections could lead to increased disease
stability. This could potentially lead to longer term im-
provement in respiratory outcomes. For example, carrying
out regular chest physiotherapy and responding appropri-
ately to symptoms of exacerbation may prevent deterior-
ation and reduce admissions. Patient self-care therefore
could make a significant difference to management.
In order to facilitate self-care, patients need to have
accurate information about their condition, empowering
them to recognise changes, respond to them and under-
stand how their self-management could potentially alter
their prognosis. The BTS guidelines for the management
of bronchiectasis [14] recommend education of patients
within their management plan. There is relatively little
information produced for patients with bronchiectasis.
Sources include a one-page leaflet produced by the British
Lung Foundation (BLF) and limited online resources. The
BTS has a brief self-management tool for bronchiectasis
that is available to download. It does not serve as an in-
formation resource but is a one-page reference guide to
exacerbation management.
In addition to the need for information and education
being recognised by organisations such as the BTS and
the BLF, a survey of 104 patients attending a specialist
bronchiectasis clinic in the North East of England found
98 % felt more confident about managing their condition
after receiving information and education about their
treatment [15]. A study using focus groups involving pa-
tients who have bronchiectasis has highlighted lack of
information as one of the perceived obstacles to self-
management [16]. In addition, a pilot study of qualitative
interviews with patients identified the importance of pa-
tient information in the process of developing the skills
and confidence to manage and live with bronchiectasis
[17, 18]. There was a strong feeling amongst participants
that there was a lack of trustworthy information (from a
reliable source such as their hospital, trusted specialists
or organisations such as the BLF) available to them be-
yond that obtained in clinic. Patients felt they would
benefit from a credible information source that they
could continue to access outside of a specialist clinic set-
ting. Despite this there remains a lack of development in
this area to date, and many chronic conditions that are
less prevalent than bronchiectasis have many more access-
ible resources.
Our yet unpublished qualitative study used in-depth
interviews with a cohort of 26 patients and carers to
identify their unmet information needs and priorities for
an information resource. We have used the themes and
needs identified during analysis of these interviews to
develop a novel patient information resource. The content
and format of the resource are based on the findings of
the interviews and subsequent focus groups with patients
and carers to refine the intervention.
A definitive, multi-centre trial would address the re-
search question: Can the provision of patient-focussed
information and education improve health outcomes in
bronchiectasis? The rationale for the Bronchiectasis Infor-
mation and Education Feasibility (BRIEF) study is that, in
advance of the definitive trial, it is necessary to assess
whether the proposed design for the trial is practicable
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and will allow the proposed outcomes to be assessed. In
addition, the intervention will be evaluated and further
refined for use within the definitive trial.
The trial will be conducted as an unblinded, rando-
mised controlled trial comparing the use of the informa-
tion resource as an intervention to usual care.
Objectives
Primary objective
The primary objective is to conduct a feasibility study
that will inform the decision of whether to proceed to
the definitive randomized controlled trial (RCT) and
whether any refinements to the design or conduct of
that trial are warranted.
Secondary objective
The secondary objective is to evaluate and further refine
the patient information resource and collect information
on patient preferences.
Definitive trial objectives
The definitive trial objectives are to assess whether
provision of a patient-focussed information and educa-
tion resource can improve patient understanding, self-
management and health outcomes in bronchiectasis.
Methods/design
Participants, interventions and outcomes
Study setting
This is a single-centre study taking place in the UK in
the Newcastle upon Tyne Hospitals NHS Foundation
Trust. This consists of two teaching hospital sites: the
Freeman Hospital and the Royal Victoria Infirmary. Study
visits will all take place within the Freeman Hospital. The
running of the trial will be based within the Freeman
Hospital at the William Leech Clinical Trials Centre.
Patients will be recruited from either hospital site.
Eligibility criteria
Inclusion criteria To fulfil the inclusion criteria, the
participant must:
1. Have the capacity to provide written informed
consent
2. Be aged 18 years or older
3. Have received a clinical and radiological diagnosis of
bronchiectasis
4. Be English speaking
Exclusion criteria The exclusion criteria include:
1. Cognitive impairment
2. Non-English speaking
3. Age <18 years
4. Participation in the preceding Bronchiectasis
Information and Education (BRIE) study
Due to the nature of the study, knowledge of the English
language is a necessary inclusion criterion to ensure us-
ability of the information provided. As this is a small
feasibility study, resources are not currently available to
produce the information in other languages or to provide
funded Internet access. For those potential participants
who do not have Internet access yet wish to take part
in the study, the information within the website (ex-
cluding video clips) can be provided in PDF format.
This will be recorded on the Case Report Form
(CRF), and the participant will proceed with the same
visits and outcomes.
Study intervention details
The BRIEF study will compare the patient information
resource (developed within the previously conducted quali-
tative study) with usual care. At the baseline visit, partici-
pants randomised to the intervention will receive the
patient information resource: an overview booklet and
website. Verbal and written instructions will be given
by appropriate members of the research team (as per
the delegation log) about how to access the website.
The participants will then have access to the interven-
tion for the duration of the study. Their use or not of
the information resource will be down to individual
choice, yet through discussion with the research team
member conducting each study visit participants will be
encouraged to utilise the resource and to allow their
families or carers to utilise it also should they so wish.
Some participants may not have direct access to a com-
puter or Internet use. This does not preclude them
from entry as long as they can access the Internet via
their family, friends or local institutions such as librar-
ies. For those who do not wish or do not have the skills
to access the website, participation using a PDF version
of the information contained within the website will be
offered. This will enable them to view all information
except the video clips. At study completion, those ran-
domised to the intervention group will be allowed con-
tinued access to the resource. Those in the control
group will be offered access to the resource following
completion of their study period so as to minimise dis-
appointment due to their allocation to the control arm.
Any uptake of the resource following study completion
does not form part of data collection.
This is a non-clinical intervention, and we do not ex-
pect any reasons for discontinuing the intervention
other than participant preference. Any participant may
choose to leave the study at any point with no effect on
usual care. Potential participants currently participating
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in another trial would not be approached for entry into
the study.
Study design and outcome measures
See Fig. 1 and Table 1.
Design This feasibility study is an unblinded, single-
centre randomised controlled trial with two parallel
groups that compares a novel patient information re-
source to usual care in bronchiectasis.
Duration The study duration for each participant will
be 3 months from the study entry date. Due to variations
in month length, this will be calculated at 12 weeks
(84 days). The study completion date will be after the
date of the last assessment visit of the last entrant and
completion of the final focus group.
Outcome measures The outcome measures are as
follows:
1. Ability to recruit adequate numbers of participants
(ratio of consented participants to potentially eligible
participants approached)
2. Numbers completing study
3. Numbers completing study scale forms,
questionnaires and visits
4. Resource satisfaction questionnaire
Fig. 1 Study flow chart
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5. Recorded use of resource and alternative
information seeking
6. Quality of Life Questionnaire-Bronchiectasis (QOL-B)
7. St George’s Respiratory Questionnaire (SGRQ)
8. Hospital Anxiety and Depression Scale (HADS)
9. Fatigue Impact Scale (FIS)
10. Euroqol 5-dimension (quality of life scale), EQ-5D
11. Number of unscheduled visits to primary or
secondary care
12. Exacerbation frequency
13. Forced expiratory volume in 1 second (FEV1)
14. Knowledge of condition and management
questionnaire
All outcome measures will be used in assessing the
feasibility of a future definitive trial, including recruit-
ment, retention and study scale form completion rates.
Participant evaluation of acceptability of the newly devel-
oped package will be established through a questionnaire
and open questioning to include their satisfaction with the
information provided, knowledge about their condition
and management, and additional features that they feel
may strengthen the intervention. Use of the resources pro-
vided and preferred formats identified within these ques-
tionnaires will also inform feasibility of a future trial and
allow refinement of intervention formats. Focus groups will
also be held to strengthen data on the patient experience.
Outcome measures will be recorded at baseline (day 0)
and then at 2 weeks (day 14) (that is, shortly after
initial viewing of information in order to facilitate
obtaining first opinions) and 3 months (day 84) post
recruitment. This will be done during patient visits
that are anticipated to take less than 1 hour each.
Visit 2 can be done via telephone interview if partici-
pants prefer.
The time taken to complete the scales and estimates
of variability in outcome measures for the population at
the various time points, with associated confidence in-
tervals, will help to inform a future sample size calcula-
tion for a definitive RCT. We will describe these data as
a reference for this patient group and as baseline mea-
sures to inform a future RCT. We will examine the rela-
tionship between outcomes and baseline covariates in
order to identify any efficacy gains through the use of
stratification in a future full RCT.
EQ-5D will be used to allow some estimate of health
economic evaluation for a future RCT. We anticipate
potential health economic benefits with patients empow-
ered to self-manage, thereby reducing service use. The
number of unscheduled presentations, exacerbation rate
and FEV1 could potentially be used in a future full trial
as a representation of the patients’ ability to self-manage
their condition. This information will be retrieved from
the patient visits and patients’ symptom and information
sheets (patients will be asked to complete a monthly
postal record sheet [at weeks 4, 8 and 12] enabling iden-
tification of episodes of change in symptoms and actions
taken, in addition to any information resource use, with-
out the burden of a daily diary record) and also through
general practitioner (GP) and hospital recorded atten-
dances if patients are unable to report or recollect.
Participants
Potential participants will be identified by case note review
and attendance at outpatient clinics and will be given or
sent a letter of invitation to the study and a patient infor-
mation sheet. Written informed consent will be obtained
Table 1 Study visits and data collection
Visit 1 Day 0 Visit 2 Week 2
(Day 14)
Visit 3: final visit Week 12
(Day 84)
Written informed consent and randomisation (if not done prior to visit 1)
and collection of baseline demographics
x
Resource use (not baseline visit) and information seeking (x) x x
Resource satisfaction questionnaire x x
Bronchiectasis knowledge questionnaire x x x
QOL-B x x x
SGRQ x x
HADS x x x
FIS x x
EQ-5D x x x
Number of unscheduled visits x x x
Exacerbation frequency x x x
FEV1 x (if not done in
past 3 months)
x
QOL-B Quality of Life Questionnaire-Bronchiectasis, SGRQ St. George’s Respiratory Questionnaire, HADS Hospital Anxiety and Depression Scale, FIS Fatigue Impact
Scale, EQ-5D Euroqol 5-dimension (quality of life scale), FEV1 forced expiratory volume in 1 second
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from willing participants (see Additional file 1). Patients
can withdraw consent at any point with no effect on usual
care. At the end of the study, some participants will be in-
vited to attend a focus group and a possible in-depth
interview about their experience. For this section of the
study only, if participants in the intervention group indi-
cate that their partner/family member or friend has also
used the resource, then they may be invited to attend dis-
cussion groups also. Up to a maximum of 10 additional
participants will be recruited for this purpose. Additional
information sheets and consent forms have been produced
for these participants (see Additional file 2). Participants
invited to attend the focus group will be sampled purpos-
ively. The intent is to form a group that includes partici-
pants of differing backgrounds and time since diagnosis,
some from the control and some from the intervention
group, and those who had differing preferences in terms
of format used. Involvement in the focus group, however,
is an optional extra, and as such a pragmatic approach will
have to be taken. Anyone agreeing to take part in the
focus group will be invited to bring along their ‘carer’, who
will then be sent the appropriate information sheet to
consider whether they would like to take part.
Participant identification and screening
Patients will be identified through case note review and
clinic attendance. Eligible participants will be invited to
participate by their consultant, the principal investigator
(PI) or the chief investigator (CI), who is part of the
medical team. The study will be explained to them further
by the research team. A study Participant Information
Sheet will be provided at this time, which the patient can
take away for consideration. For those identified by case
note review, a letter of invitation will be sent in the post
along with the Participant Information Sheet and details
of how to get in touch if interested. They will be offered the
opportunity to discuss this further with the research team.
A screening log will be kept to document details of
subjects invited to participate in the study. For subjects
who decline participation, this will document any reasons
available for non-participation. The log will also ensure
potential participants are only approached once.
Sample size
The sample size will be 70, with a minimum of 30 being
randomised to each arm. This is based on previous rec-
ommendations for good practice in feasibility studies
[19]. Because this is a feasibility study, no formal power
calculations have been carried out. Up to 10 non-patient
(carer) participants will be recruited for the qualitative
section of the study, as discussed in the section ’Focus
group data’.
We anticipate that 24 months will be adequate time
to recruit 70 patients to this study, based on a clinic
attendance of approximately 60 per month with an esti-
mate of 50 % of patients approached who are willing
and able to enter. Seventy patients recruited from ap-
proximately 140 patients approached would correspond
to a 95 % confidence interval for the recruitment rate
of 41–59 % (an acceptable width of ±9 %). We expect
low attrition rates based on previous work and our prior
experience in this field. There will be a 3-month additional
period for follow-up of the last recruited participants and
time beyond for the interviews, focus groups and analysis.
Assignment of intervention
Randomisation
Participants will be randomised to intervention or con-
trol in a 1:1 ratio, using random permuted blocks within
strata. Randomisation will be stratified by gender. The
randomisation allocation schedule will be generated by a
statistician with no other involvement in the study.
Randomisation will be performed by the CI at site, or
an individual with delegated authority, using a secure
password-protected web-based system administered by
Newcastle Clinical Trials Unit. Randomisation will gen-
erate a unique 3-digit study identification number for
each participant. Participants will be informed of their
allocated treatment group following randomisation.
Blinding is not feasible for this study for patients or the
research team conducting the study visits due to the
nature of the intervention. The data analyst is also in-
volved directly with the study processes and data col-
lection, and thus blinding of the analyst is not possible.
Data collection, management and analysis
Data collection
Data will be collected at study visits by the research
team as per the delegation log. Visits 1 and 3 will be
done in person; visit 2 can be either in person or on the
telephone. Other than breathing tests at visits 1 and 3,
all outcome measures are questionnaires and will be ei-
ther self-completed by the participants or completed
with the help of the research team member conducting
the study visit. All answers will be recorded in paper
copies of each questionnaire within the CRF. The study
team member conducting the visit will check for omis-
sions after completion with the participant. All members
of the delegate log will be trained in the use of the ques-
tionnaires and lung function tests. The questionnaires to
be completed are summarised in Table 2. Additional
data collection will be obtained via monthly (weeks 4, 8,
12) postal symptom and resource use record sheets sent
to participants. This will enable more accurate recollec-
tion of symptoms and information use than at the study
visits alone, yet is a reduction in burden as compared to
completing a daily diary. Phone calls will be made to en-
courage completion if the forms are not returned.
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Focus group data
A number of participants will be invited to a focus group
to discuss participation in the trial and views on further
refinements to the intervention and the study protocol.
Should specific issues arise within the focus groups that
need further exploration, then a number of in-depth in-
terviews may also be held. These would be entirely op-
tional. If participants indicate that their partner, family
member or friend has used the resource, then they may
be invited to this section of the study also. A maximum
of 10 carers will be recruited and given the appropriate
Participant Information Sheet, and written informed
consent will be obtained. Thematic analysis will be used
to look for patterns of meaning and ‘themes’ in the data
content. Data will be organised into meaningful groups
to identify and describe themes and issues raised in the
interviews.
Data handling and record keeping
Data collected on paper CRFs will be entered by the CI
or appropriately trained study delivery staff and data man-
ager (as per the delegation log) on a secure password-
protected study computer. Participants will be identifiable
only by a unique study identifier on all recorded data.
Focus group audio files will be transcribed verbatim.
All data will be stripped of strong identifiers and will
only be identified by a unique study number, and only
authorised members of the research team, operating to
written codes of confidentiality, will have access to the
link between anonymised data and patient/professional
identifiable details. Patients and professionals will not be
identifiable in any publications emanating from the work
described in this application. Data will be handled, com-
puterised and stored in accordance with the Data Pro-
tection Act 1998. No participant identifiable data will
leave the study site.
Compliance and withdrawal
Compliance Where feasible, study visits will coincide
with routine clinical follow-up to enhance the likelihood
of good compliance. Visit windows of 2 weeks should
ensure visit attendance; non-attendance for study visits
will prompt follow-up by telephone. Participants will be
given the option of completing visit 2 by telephone
interview to reduce the burden of travel for study visits.
Non-return of monthly postal record sheets will also
prompt follow-up by telephone.
Withdrawal of participants Participants have the right
to withdraw from the study at any time for any reason
and without giving a reason. The investigator also has
the right to withdraw patients from the study interven-
tion if she/he judges this to be in the patient’s best inter-
ests. It is understood by all concerned that an excessive
rate of withdrawals can render the study uninterpretable;
therefore, unnecessary withdrawal of patients should be
avoided. Should a patient decide to withdraw from the
study, all efforts will be made to report the reason for
withdrawal as thoroughly as possible.
There are two withdrawal options:
1. Withdrawing completely (withdrawal from both the
study intervention and provision of follow-up data)
2. Withdrawing partially (withdrawal from the study
intervention but continuing to provide follow-up
data by attending clinic and completing
questionnaires)
Consent will be sought from participants choosing
option 1 to retain data collected up to the point of
withdrawal. Participants will be asked if they would
allow the reason for the decision to withdraw to be
recorded.
Statistical analysis
A statistical analysis will be performed using SPSS 17.0.
As this is a feasibility study, the analyses of the data col-
lected will be mainly descriptive, with 95 % confidence
intervals reported where appropriate. As a randomised
controlled trial, the primary analysis will be based on the
intention-to-treat principle with analysis groups based
on the groups allocated at randomisation and all rando-
mised patients being included in the analysis. As a feasi-
bility study, the extent of missing data will be assessed
Table 2 Outcome measures
Study instrument Description
Resource use and
information seeking
Unvalidated questionnaire
Resource satisfaction
questionnaire
Unvalidated questionnaire
Bronchiectasis knowledge
questionnaire
Unvalidated questionnaire
QOL-B Validated Quality of Life Questionnaire-
Bronchiectasis [26]
SGRQ Validated St George’s Respiratory
Questionnaire [3]
HADS Validated Hospital Anxiety and Depression
Scale [27]
FIS Validated Fatigue Impact Scale [28]
EQ-5D Validated Euroqol 5-dimension quality of
life questionnaire [29]
Number of unscheduled
visits
Patient’s report of healthcare visits
Exacerbation frequency Patient’s report of number of
exacerbations
FEV1 (absolute value and
% predicted)
Lung function test (forced expiratory
volume) using calibrated equipment
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and reported, and analysis of outcomes may also be
carried out on a complete-case basis. Rates will be cal-
culated as defined and reported with 95 % confidence
intervals. At baseline and by intervention group the
distribution of all numerical variables will be examined
and summarised using measures of location and spread.
Similarly, baseline categorical variables will be tabulated
and percentages reported. Change in the questionnaire
outcomes from baseline to 2 weeks and 3 months will be
summarised. The difference in the mean change between
the intervention groups from baseline to each of the two
time points will be explored for all outcome measures and
reported with accompanying 95 % confidence intervals.
Such results will be interpreted cautiously because of
the size of the study and the possible imbalance in pre-
randomisation baseline covariates. The relationship be-
tween baseline covariates and outcome measures will
be examined graphically and quantified appropriately
depending on their distribution. No formal statistical
testing will be performed. Confidence limits for the es-
timated standard deviations of key study parameters
will be calculated and used in sensitivity analyses for
sample size calculations for a future definitive RCT.
Monitoring
This is a low risk trial, and major safety data are not
anticipated. As agreed upon by Newcastle upon Tyne
Hospitals, the Trial Oversight Committee (TOC) will
adopt the joint roles of Trial Steering Committee (TSC)
and Data Monitoring and Ethics Committee (DMEC) with
independent members meeting in closed session to fulfil
the DMEC role. The TOC comprises an independent
chair, an independent consumer representative, a patient
representative, a carer representative, CI, PI, data manager
and statistician. The TOC will meet bi-annually. Their role
is to monitor progress and supervise the trial to ensure it
is conducted to high standards in accordance with the
protocol, the principles of good clinical practice (GCP)
and relevant regulations and guidelines and with regard to
participant safety. The purpose of this committee will be
to monitor study progress and patient safety. Monitoring
of study conduct and data collected will be performed by
site review to ensure the study is conducted in accordance
with GCP. The main areas of focus will include consent,
serious adverse events and essential documents in study.
The study may be subject to inspection and audit by
Newcastle upon Tyne Hospitals under their remit as
sponsor and by other regulatory bodies to ensure adher-
ence to GCP. The investigator(s)/institutions will permit
trial-related monitoring, audits, Research Ethics Commit-
tee (REC) review and regulatory inspection(s), providing
direct access to source data/documents.
There is no interim analysis planned for this study.
Adverse event monitoring and reporting
Definitions
Adverse event (AE) An AE is an untoward medical oc-
currence in a subject to whom a study intervention or
procedure has been administered, including occurrences
which are not necessarily caused by or related to that
intervention. An AE, therefore, does not necessarily have
a causal relationship with the treatment. In this context,
‘treatment’ includes all interventions (including compara-
tive agents) administered during the course of the study.
Medical conditions/diseases present before starting study
treatment are only considered AEs if they worsen after
starting study treatment.
Related adverse event A related AE is one that results
from administration of any of the research study proce-
dures. All AEs judged by either the reporting investigator
or the sponsor as having reasonable causal relationship to
a study procedure qualify as ‘related adverse events’. The
expression ‘reasonable causal relationship’ means to
convey in general that there is evidence or argument to
suggest a causal relationship.
Causality The assignment of the causality should be
made by the investigator responsible for the care of the
participant using the definitions in Table 3. All AEs
judged as having a reasonable suspected causal relation-
ship to a study procedure (that is, definitely, probably or
possibly related) are considered to be related AEs. If any
doubt about the causality exists, the local investigator
(PI) should inform the CI. In the case of discrepant
Table 3 Definitions of causality
Relationship Description
Unrelated There is no evidence of any causal relationship
Unlikely There is little evidence to suggest there is a
causal relationship (e.g. the event did not
occur within a reasonable time after
administration of the study procedure). There
is another reasonable explanation for the event
(e.g. the participant’s clinical condition or other
concomitant treatment)
Possible There is some evidence to suggest a causal
relationship (e.g. because the event occurs
within a reasonable time after administration
of the study procedure). However, the
influence of other factors may have contributed
to the event (e.g. the participant’s clinical
condition or other
concomitant treatments)
Probable There is evidence to suggest a causal relationship
and the influence of other factors is unlikely
Definitely There is clear evidence to suggest a causal
relationship and other possible contributing
factors can be ruled out
Not assessable There is insufficient or incomplete evidence to
make a clinical judgement of the causal relationship
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views on causality between the investigator and others,
all parties will discuss the case. In the event that no
agreement is made, the main REC and other bodies will
be informed of both points of view.
Unexpected adverse event
An unexpected AE is one that is not listed in the study
protocol as an expected occurrence in the circumstances
of this trial.
Serious adverse event (SAE)
An SAE is an untoward occurrence (whether expected
or not) that:
 Results in death
 Is life-threatening (refers to an event in which the
subject was at risk of death at the time of the event;
it does not refer to an event which hypothetically
might have caused death if it were more severe)
 Requires hospitalisation or prolongation of existing
hospitalisation
 Results in persistent or significant disability or
incapacity
 Consists of a congenital anomaly or birth defect
 Is otherwise considered medically significant by the
investigator
Medical judgement should be exercised in deciding
whether an AE is serious in other situations. Important
medical events that are not immediately life-threatening
or do not result in death or hospitalisation but may jeop-
ardise the patient or may require intervention to prevent
one of the other outcomes listed in the definition above
should also be considered serious.
Severity (intensity) of adverse events and adverse reactions
The severity of all AEs will be graded on a three-point
scale of intensity (mild, moderate and severe):
 Mild: Discomfort is noticed, but there is no
disruption of normal daily activities.
 Moderate: Discomfort is sufficient to reduce or
affect normal daily activities.
 Severe: Discomfort is incapacitating, resulting in
inability to work or to perform normal daily activities.
An AE may be severe but not serious.
Expected adverse reactions
This is a low risk study, and there are no expected ad-
verse reactions (ARs) from the intervention as it is an
information resource rather than a treatment. Study
procedures in the main are completing forms. Very oc-
casionally when people perform spirometry (which will
be measured at study visits) they may feel light headed
for a short while afterwards. Spirometry tests will be per-
formed seated, and if participants have a known tendency,
this test will be omitted. As this is a rare but expected AR,
it would not be reported. Only suspected unexpected
serious adverse reactions (SUSARs) will be reported.
Recording and reporting adverse events or reactions
All AEs should be reported as per protocol specifications.
Depending on the nature of the event, the reporting
procedures in the succeeding paragraphs should be
followed. Any questions concerning AE reporting should
be directed to the CI or PI in the first instance.
Adverse events
All non-serious AEs during study participation will be
reported on the study CRF and sent to the CI within
2 weeks of the form being due. Severity of AEs will be
graded on a three-point scale (mild, moderate and severe).
Relation (causality) and seriousness of the AE to the treat-
ment should be assessed by the investigator at site in the
first instance. The individual investigator will be respon-
sible for managing all AEs according to local policy.
Serious adverse events
All SAEs during study participation shall be reported to
the CI within 24 hours of the site learning of its occur-
rence. The initial report can be made by telephone or
email. Use of the SOHO66 fax system ensures that the
NCTU, sponsor and CI are all informed by email
simultaneously.
In the case of incomplete information at the time of
initial reporting, all appropriate information should be
provided as follow-up as soon as it becomes available.
The relationship of the SAE to study procedures should
be assessed by the investigator at site, as should the ex-
pected or unexpected nature of the SAE.
Ethics and dissemination
Ethics and regulatory issues
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki, 1964 and later revisions.
Favourable ethical opinion from NRES Committee
North East - Sunderland (reference 14/NE/0119) has
been granted, and R&D approval (reference 7005) from
the Newcastle upon Tyne Hospitals NHS Foundation
Trust was granted prior to commencement of the study.
Any protocol amendments will be approved by R&D
and the Sunderland REC and will be communicated to
all relevant parties: investigators, registries, participants.
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Information sheets will be provided to all eligible sub-
jects and written informed consent obtained prior to any
study procedures.
Informed consent procedures
Informed consent discussions will be undertaken by ap-
propriately trained site staff (as per the delegation log)
involved in the study, including medical staff and research
nurses, with the opportunity for participants to ask any
questions. Following receipt of information about the
study, participants will be given reasonable time (aiming
for a minimum of 24 hours) to decide whether or not they
would like to participate. Those wishing to take part will
provide written informed consent by signing and dating
the study consent form, which will be witnessed and dated
by a member of the research team with documented, dele-
gated responsibility to do so. Written informed consent
will always be obtained prior to randomisation and prior
to study-specific procedures/investigations.
The original signed consent form will be retained in
the Investigator Site File, with a copy in the clinical notes
and a copy provided to the participant. The participant
will specifically consent to his/her GP being informed of
their participation in the study.
The right to refuse to participate without giving reasons
will be respected.
Due to the small subject population and the inclusion
criteria, the information sheet and consent form for the
study will be available only in English.
Confidentiality
Personal data will be regarded as strictly confidential.
To preserve anonymity, any data leaving the site will
identify participants by their initials and a unique study
identification code only. The study will comply with the
Data Protection Act 1998. All study records and Inves-
tigator Site Files will be kept at site in a locked filing
cabinet with restricted access. Only members of the re-
search team will have access to the final dataset and ac-
cess as required for necessary audit and monitoring.
Insurance and finance
The sponsor, the Newcastle upon Tyne Hospitals NHS
Foundation Trust, has liability for clinical negligence
that harms individuals toward whom they have a duty of
care. NHS indemnity covers NHS staff and medical aca-
demic staff with honorary contracts conducting the trial
for potential liability in respect of negligent harm arising
from the conduct of the study. The Newcastle upon
Tyne Hospitals NHS Trust is sponsor and, through the
sponsor, NHS indemnity is provided in respect of po-
tential liability and negligent harm arising from study
management. Indemnity in respect of potential liability
arising from negligent harm related to study design is
provided by NHS schemes for those protocol authors
who have their substantive contracts of employment
with the NHS and by Newcastle University insurance
schemes for those protocol authors who have their sub-
stantive contract of employment with the university.
This is a non-commercial study, and there are no arrange-
ments for non-negligent compensation. Newcastle Univer-
sity provides insurance coverage for the trial design.
The National Institute for Health Research (NIHR) is
funding the study through a doctoral research fellowship
awarded to the CI.
Study reporting and publications
It is planned to publish this study in peer-reviewed arti-
cles and to present data at national and international
meetings. Results of the study will also be reported to
the sponsor (Newcastle upon Tyne Hospitals) and funder
(NIHR) and will be available on their websites. All manu-
scripts, abstracts or other modes of presentation will be
reviewed by the Trial Overview Committee and funder
prior to submission. This will also form part of the PhD
thesis of the CI. Individuals will not be identified from any
study report. Participants will be informed about their
contribution to the study, including a lay summary of the
results, at the end of the study.
Discussion
This study is a low risk study. As the study and inter-
vention have been co-developed with potential users,
we hope this will make the trial process and use of the
resource straightforward and beneficial. The study will
both inform a future multi-centre trial and allow for
evaluation and refinement of the patient information
resource to maximise potential future uptake and impact.
Analysis of outcome measures will begin to determine
impact of this novel information resource on patient
knowledge and confidence to self-manage and inform
development of a definitive trial to determine the effect
on disease stability.
The relatively short duration of the feasibility study
may limit the usefulness of exacerbation frequency data
in terms of defining this rate for a definitive trial. We
are collecting these data to determine the feasibility of
their use as an outcome measure, yet for a definitive trial
with a longer follow-up period, it is likely that we would
need to refer to previously published rates of exacerba-
tion frequency in bronchiectasis. Within a recent ana-
lysis of 155 patients at our centre this was found to be
roughly 4 per annum [20], although this does differ be-
tween publications as outlined in the BTS guidelines for
the treatment of bronchiectasis [14]. It has also been
demonstrated that exacerbation rates vary seasonally
[21], and with a shorter feasibility study frequency is
therefore harder to extrapolate accurately. Additionally,
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in terms of reporting of exacerbations, within this study
design we have relied upon patient reporting of numbers
of exacerbations for which they have required treatment
with a course of antibiotics. We have not included a
strict definition of an exacerbation within the protocol
as we have not asked patients to report changes in
symptoms in real time nor made decisions about diagno-
sis of exacerbations or treatment for them. We do not
anticipate a significant problem with ascertainment bias,
yet consideration of this will also help to inform the de-
finitive trial. Due to the short amount of time between
visits in this study, we do not anticipate issues with re-
call, although patient notes can be used as an alternative
mechanism.
One of the potential impacts of the intervention will
be to improve symptom recognition and management.
This will not, however, be a uniform change. Some par-
ticipants were likely to have under-recognised exacer-
bations prior to study participation, and others were
possibly taking courses of antibiotics for symptoms they
felt were indicative of an exacerbation that were in fact
just ‘normal’ variations in their chronic symptoms. Thus,
using number of courses of antibiotics or change in
number is not necessarily a useful measure; hence the
additional recording of unscheduled healthcare usage.
The addition of qualitative data through the use of
focus groups will allow for a richer exploration of the
experience of both the trial process and use of the infor-
mation package for participants. Although we know that
patients want more information about bronchiectasis
[17], it is argued that health information alone does
not necessarily produce changes in behaviour [22]. How-
ever, asthma studies have shown that delivering education
about the key aspects of the condition, allowing patients
to acquire skills, and education in combination with
clinical review and action plans can lead to demonstrable
improvements [23–25]. By providing improved educa-
tional interventions that meet the needs of patients with
bronchiectasis and their carers, we aim to facilitate im-
provements in self-management. Our aim is that in
addition to providing a resource that is a reassuring
source of support for patients and carers, improve-
ments in understanding and management will lead to
improvements in health outcomes and healthcare ser-
vice use longer term. By evaluating and refining this
patient-driven intervention and assessing the feasibility
of conducting a future definitive RCT, we are making
important progress in the provision of much needed in-
terventions in bronchiectasis.
Trial status
The study is still recruiting at time of submission. The
first recruit was on 10/6/2014.
Additional files
Additional file 1: Patient consent form. (DOC 103 kb)
Additional file 2: Carer consent form. (DOC 102 kb)
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